Sentient Jet at the Forefront of Sustainability in Private Aviation Industry With Over 300% Emissions Offset Projected For 2022
25.7.2022 16:00:00 EEST | Business Wire | Press release
Sentient Jet, a Directional Aviation company and category innovator, is set to surpass its notable 2021 sustainability efforts of offsetting one of, if not the highest amount of emissions of any private aviation company with the first half of 2022 on the rise. As a multi-million-dollar annual investment at no cost to its card owners, Sentient Jet’s strong commitment to sustainability continues to set a new industry standard while offering a more thoughtful way to fly.
Sentient Jet launched its emissions-neutral sustainability initiative at the start of 2021 and promptly achieved the largest emissions offset of any private aviation company, with a 300% offset across 30,000 legs flown through the year.
Sentient’s offsets represent the equivalent of planting 345,000 acres and nearly 5,000,000 trees in the U.S. or providing the energy for an entire average U.S. town for a full year, according to current U.S. Census Bureau estimates for 2021. Sentient Jet’s carbon offset program supports a variety of renewable energy and forest conservation projects around the world and continues to fund projects to mitigate not only CO2 but non-CO2 impact and improve communities globally.
“We chose to focus on a more comprehensive offsetting program, as we knew this was the best method to help reduce the footprint of our client’s flights while also taking definitive steps to reducing emission levels. Within 18 months we’re extremely pleased with the success of this program, but of course we’re always looking for ways to improve and evolve our ongoing sustainability efforts,” said Andrew Collins, President and CEO of Sentient Jet. “We hope Sentient Jet’s sustainability efforts can become an example for what the private aviation industry as a whole can accomplish in terms of making meaningful steps toward reducing overall emissions and prioritizing our planet.”
At the heart of Sentient Jet’s unique sustainability initiative is the company’s investment and partnership with environmental leader 4AIR, the first and only rating system focused on comprehensive sustainability in private aviation. Sentient Jet’s carbon offset program goes beyond traditional aviation sustainability programs by offsetting all aviation emissions, including water vapor, aerosols, and nitrous oxide, which together account for two-thirds of the emissions an aircraft produces when flying.
“Sentient Jet continues to demonstrate true leadership by committing all of its flights to 4AIR’s Emissions Neutral level on behalf of its clients. Sentient goes beyond just carbon neutrality, addressing the impact from CO2 and non-CO2 emissions in a truly comprehensive fashion,” says Kennedy Ricci, President, 4AIR.
Jet Card owners can book by calling (866) 602-0044 or visiting www.sentient.com.
About Sentient Jet
Founded in 1999 with the invention of the Jet Card, and now an integral part of Directional Aviation, Sentient Jet is one of the most innovative private aviation companies across the globe. The Sentient Jet Card offers clients the flexibility and convenience of flying private for their personal and business air travel needs along with a host of unique digital booking tools, including an industry-first with instant, automated text-based booking, a unique sustainability program, and an outstanding service heritage. Sentient Jet is known for its commitment to safety and is guided by an Independent Safety Advisory Board with former FAA and NTSB officials. Sentient Jet’s extensive network of certified operators ensures that clients will always have access to executive aircraft that meet their rigorous standards for safety and quality. Visit sentient.com for more information. You can also follow Sentient Jet on social media platforms, including Twitter , Facebook and Instagram. Download the Sentient Jet Mobile App: iOS | Android .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005080/en/
Contact information
Daphna Barzilay
Maverick Creative
daphna@maverickcreative.us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom